文献速递食管与纵隔外科

新辅助化疗联合免疫治疗后临床N2-3期食管鳞状细胞癌的两年结局:2期NICE研究

Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-09-09

2期NICE研究纳入60例临床N2-3期食管鳞状细胞癌患者,接受白蛋白紫杉醇+卡铂+卡瑞利珠单抗两周期新辅助治疗后手术,中位随访27.4个月,2年总生存率78.1%、无复发生存率67.9%,远处转移为主要复发模式,主要病理缓解与更低复发和更好生存相关。

要点

  • 2年OS率78.1%,2年RFS率67.9%,远处转移为最常见复发模式。
  • 达到主要病理缓解者2年OS率91.4% vs 47.7%,RFS率77.1% vs 45.9%。
  • 主要病理缓解为疾病复发的独立预后因素(HR 0.39,95%CI 0.21-0.82,P=.029)。

核心结论

  • 在接受新辅助化疗联合免疫治疗的患者中,远处转移仍是主要复发模式。
  • 主要病理缓解与更低的复发风险和更好的生存相关。
  • 仍需来自随机对照试验的长期结果。

研究设计与样本

  • 2期NICE试验(注册号ChiCTR1900026240),筛选并纳入临床N2-3期食管鳞状细胞癌患者。
  • 治疗方案为白蛋白紫杉醇(100 mg/m2,第1、8、15天)、卡铂(曲线下面积=5,第1天)、卡瑞利珠单抗(200 mg,第1天),每21天为一周期,共2周期,末次化疗后4至6周行食管切除术。
  • 2019年11月20日至2020年12月22日共入组60例患者。
  • 探索肿瘤学结局、复发模式、总生存(OS)和无复发生存(RFS)。

主要发现

  • 中位随访27.4个月,19例(37.3%)患者出现疾病复发,其中局部区域复发5例(9.8%)、远处转移9例(17.6%)、复合复发5例(9.8%)。
  • 肺是最常见的转移部位。
  • 中位复发时间为10.8个月(四分位距7.5-12.7个月)。
  • 2年OS率为78.1%,2年RFS率为67.9%。
  • 达到主要病理缓解的患者2年OS率显著更高(91.4% vs 47.7%;P<.001),2年RFS率也显著更高(77.1% vs 45.9%;P=.003)。

局限性

  • 原文结论指出仍需来自随机对照试验的长期结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to report the 2-year outcomes of patients with clinical stage N2-3 esophageal squamous cell carcinoma who received neoadjuvant chemotherapy and immunotherapy followed by surgery from a phase 2 NICE trial. METHODS: Eligible patients with clinical stage N2-3 esophageal squamous cell carcinoma were screened and enrolled, then treated with regimen of nab-paclitaxel (100 mg/m2, days 1, 8, 15), carboplatin (area under the curve = 5, day 1), camrelizumab (200 mg, day 1) of two 21-day cycles and esophagectomy 4 to 6 weeks after the last chemotherapy. Oncologic outcomes, recurrence patterns, overall survival (OS), and recurrence-free survival (RFS) were explored. RESULTS: From November 20, 2019, to December 22, 2020, 60 patients were recruited. After a median follow-up of 27.4 months, disease recurrence was observed in 19 (37.3%) patients, with 5 (9.8%) locoregional recurrence, 9 (17.6%) distant metastasis, and 5 (9.8%) combined recurrence. Lung was the most commonly involved metastatic site. The median time to recurrence was 10.8 months (interquartile range, 7.5-12.7 months). The 2-year OS and RFS rates were 78.1% and 67.9%, respectively. Patients who achieved major pathologic response (MPR) had a significantly greater 2-year OS rate (91.4% vs 47.7%; P < .001) and RFS rate (77.1% vs 45.9%; P = .003). On multivariable analysis, MPR was indicated as an independent prognostic factor for disease recurrence (hazard ratio, 0.39; 95% confidence interval, 0.21-0.82; P = .029). CONCLUSIONS: In patients receiving neoadjuvant chemotherapy and immunotherapy, distant metastasis remains the predominant recurrence pattern. MPR is associated with lower recurrence and better survival. Long-term results derived from randomized controlled trials are further required. TRIAL REGISTRATION NUMBER: ChiCTR1900026240.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Yang Y, Liu J, Liu Z, et al. Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiovasc Surg. 2023. PMID: 37696429. doi:10.1016/j.jtcvs.2023.08.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。